Carmine De Angelis

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 16 papers. Top paper: “Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer”.

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-19-4191

N/A

4.0DataRank · unranked

96 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

Scientific Reports(2022)10.1038/s41598-022-05949-7

N/A

0.912DataRank · unranked

27 citations

Hariprasad Thangavel, Noor Mazin Abdulkareem, Suhas Vasaikar, Carmine De Angelis, Leon Bae +7 more

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2975

N/A

0.907DataRank · unranked

35 citations

Agostina Nardone, Douglas Russo, Zsuzsanna Nagy, Capucine Héraud, Albert Grinshpun +26 more

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

Proceedings of the National Academy of Sciences(2016)10.1073/pnas.1612835113

N/A

0.784DataRank · unranked

185 citations

Rinath Jeselsohn, Resel Pereira, Emporia F. Hollingsworth, Chad J. Creighton, Fugen Li +22 more

Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance

Nature Cell Biology(2020)10.1038/s41556-020-0514-z

N/A

0.741DataRank · unranked

139 citations

Zhao Zhang, Yi‐Zhou Jiang, Pengya Xue, Hu Wang, Zhao Lai +16 more

Pregnancy After Breast Cancer in Young BRCA Carriers

JAMA(2024)10.1001/jama.2023.25463

N/A

0.614DataRank · unranked

59 citations

Eva Blondeaux, Elisa Agostinetto, Anne-Sophie Hamy, Hee Jeong Kim, Antonio Di Meglio +199 more

High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer

Cell Reports(2023)10.1016/j.celrep.2023.112821

N/A

0.483DataRank · unranked

24 citations

Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J. Shea, Sarmistha Nanda +17 more

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0564

N/A

0.470DataRank · unranked

22 citations

Beom-Jun Kim, Aparna Mitra, Craig T. Vollert, Jonathan T. Lei, Diana Fandino +18 more

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy

Breast Cancer Research(2025)10.1186/s13058-025-02020-x

N/A

0.360DataRank · unranked

10 citations

Giulia Cursano, Roberta Scafetta, Pier Paolo Maria Berton Giachetti, Alberto Concardi, Elisa De Camilli +21 more

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study

Annals of Oncology(2025)10.1016/j.annonc.2025.11.004

N/A

0.208DataRank · unranked

3 citations

Eva Blondeaux, Elena Tenedini, Lia Bonamici, Rossella Graffeo, L Livraghi +54 more

Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine

Tumori Journal(2013)10.1177/030089161309900333

N/A

0.165DataRank · unranked

2 citations

Monica Milano, Piera Gargiulo, Brigida Stanzione, Valeria Forestieri, Rossella Lauria +5 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603.v1

N/A

0DataRank · unranked

0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

npj Breast Cancer(2021)10.1038/s41523-021-00274-0

N/A

0DataRank · unranked

11 citations

Carolina Gutiérrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea +16 more

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer

The FASEB Journal(2021)10.1096/fj.202100070r

N/A

0DataRank · unranked

25 citations

Raksha R. Bhat, Lanfang Qin, Suhas Vasaikar, Ambily Gopinathan, Tamika Mitchell +8 more

Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.522

N/A

0DataRank · unranked

0 citations

Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Lieveke Ameye, Marianne Paesmans, Sarra El-Abed +13 more

Data from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

(2023)10.1158/1078-0432.c.6530603

N/A

0DataRank · unranked

0 citations

Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan +25 more